Aimmune Therapeutics, Inc. (AIMT): Price and Financial Metrics


Aimmune Therapeutics, Inc. (AIMT)

Today's Latest Price: $17.98 USD

0.12 (0.67%)

Updated Jun 5 12:49pm

Add AIMT to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

AIMT Daily Price Range
AIMT 52-Week Price Range

AIMT Stock Price Chart More Charts


AIMT Price/Volume Stats

Current price $17.98 52-week high $37.00
Prev. close $17.86 52-week low $10.09
Day low $17.78 Volume 561,605
Day high $18.91 Avg. volume 1,538,676
50-day MA $16.39 Dividend yield N/A
200-day MA $23.66 Market Cap 1.17B

Aimmune Therapeutics, Inc. (AIMT) Company Bio


Aimmune Therapeutics is a clinical-stage biopharmaceutical company, engages in the development of desensitization treatments for peanut and other food allergies. The company was founded in 2011 and is based in Brisbane, California.


AIMT Latest News Stream


Event/TimeNews Detail
Loading, please wait...

AIMT Latest Social Stream


Loading social stream, please wait...

View Full AIMT Social Stream

Latest AIMT News From Around the Web

Below are the latest news stories about Aimmune Therapeutics Inc that investors may wish to consider to help them evaluate AIMT as an investment opportunity.

Aimmune Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference

Aimmune Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference

Yahoo | June 4, 2020

New PALFORZIA™ Data on Long-Term Safety, Efficacy and Immunomodulation and New Data on Patient Satisfaction with PALFORZIA Treatment to be Presented at EAACI 2020 Congress

New PALFORZIA™ Data on Long-Term Safety, Efficacy and Immunomodulation and New Data on Patient Satisfaction with PALFORZIA Treatment to be Presented

Yahoo | June 1, 2020

Largest European Quantitative Study on Peanut Allergy Confirms Significant Need, Burden and Psychosocial Impact of Peanut Allergy on Allergic Individuals and their Caregivers

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for life-threatening food allergies, today announced that findings from APPEAL-1 (Allergy to Peanuts ImPacting Emotions And Life-1), a multi-dimensional pan-European study assessing the psychosocial effect and impact of living with peanut allergy, were published in Allergy, one of the official journals of European Academy of Allergy and Clinical Immunology (EAACI). The study, published in two parts (Part A and Part B), highlights the substantial impact peanut allergy has on every aspect of allergic individuals’ and their caregivers’ lives, including the uncertainty they feel around how to manage frightening and debilitating reactions and concerns about the feasibility of ongo...

Yahoo | May 28, 2020

Some Analysts Just Cut Their Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Estimates

The latest analyst coverage could presage a bad day for Aimmune Therapeutics, Inc. (NASDAQ:AIMT), with the analysts...

Yahoo | May 19, 2020

Why Are So Many Traders Betting Against the First Therapy for Peanut Allergies?

Short-sellers are convinced a company marketing the first approved biologic for treating peanut allergies in children and teenagers will fail. Here's why.

Yahoo | May 16, 2020

Read More 'AIMT' Stories Here

AIMT Price Returns

1-mo 3.93%
3-mo -12.76%
6-mo -39.36%
1-year -8.08%
3-year 1.75%
5-year N/A
YTD -46.28%
2019 39.92%
2018 -36.75%
2017 84.94%
2016 10.84%
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9049 seconds.